Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

40.78USD
27 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$40.78
Open
--
Day's High
--
Day's Low
--
Volume
200
Avg. Vol
3,254,022
52-wk High
$45.58
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

GSK still in talks with AstraZeneca about start date for Luke Miels
Wednesday, 26 Apr 2017 10:26am EDT 

April 26 (Reuters) - GlaxoSmithKline Plc CEO Emma Walmsley told analysts::"no comment" on whether would launch authorised advair generic in u.s..still in discussion with AstraZeneca about date for Luke Miels to join GSK.  Full Article

New GSK plans to sharpen priorities in drug development
Wednesday, 26 Apr 2017 07:01am EDT 

April 26 (Reuters) - GlaxoSmithKline CEO Emma Walmsley told reporters::still lot of uncertainty around generic Advair.focus now on execution, since next wave of new drug launches is in early 2020s.priority in short term is focusing on opportunities with new drug launches, including Shingrix and closed triple.long term priority must be around strengthening pharma pipeline.need to make tough choices around allocation of capital in pharma.sees logic and benefit in having broad company with 3 business units.all 3 businesses must continue to perform competitively and gsk must remain best owner.still digesting Novartis transaction but watching opportunities for M&A.M&A most likely to bolster early-stage drug pipeline.wants bigger returns from pharma research and development investment.wants to bring commercial voice in much earlier in drug development.wants fewer but bigger drug launches in future.will need to switch off some areas of drug development.  Full Article

GSK seeks Japanese approval for shingles vaccine
Tuesday, 18 Apr 2017 04:16am EDT 

April 18 (Reuters) - GlaxoSmithKline Plc ::Gsk vaccine submission for shingles in japan.JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix.  Full Article

GSK makes changes to financial reporting; sees growth in emerging markets
Tuesday, 11 Apr 2017 07:02am EDT 

GlaxoSmithKline Plc : Change to financial reporting framework . As a result of its latest review, GSK will be making following change to its financial reporting from Q1 2017. . Core results will be renamed adjusted results and will include 'ordinary course' legal charges . From Q1 2017, only significant legal charges and expenses will be excluded in order to present adjusted results. . Change is not expected to affect group's previously announced guidance for 2017 or group's outlook for five-year period 2016-2020 . Target expectation of at least 6 bln stg of revenue/ year on a CER basis by 2020 from products launched since 2013 is now expected to be met up to 2 yrs earlier .Expects volume demand for its products to increase, particularly in emerging markets.  Full Article

GlaxoSmithKline files for debt shelf of up to $10 bln - SEC Filing
Monday, 3 Apr 2017 05:45pm EDT 

GlaxoSmithKline Plc : Files for debt shelf of up to $10 billion - SEC Filing .GlaxoSmithKline - The debt securities will be issued by co or through one of its finance subsidiaries.  Full Article

Mylan receives CRL for generic Advair Diskus ANDA
Wednesday, 29 Mar 2017 01:16pm EDT 

Mylan NV : Mylan comments on generic Advair Diskus abbreviated new drug application . In conjunction with Mylan's GDUFA goal date, company received a complete response letter from FDA regarding its ANDA for generic Advair Diskus .Is in process of reviewing the response and will provide an update on its application as soon as practicable once it has completed its review.  Full Article

Mylan says no comment at this point on U.S. generic Advair application
Wednesday, 29 Mar 2017 07:30am EDT 

Mylan : Spokeswoman says company has no comment at this point on its U.S. FDA application for generic copy of GlaxoSmithKline's Advair . For more on this story see [nL5N1H6149] Further company coverage: [MYL.O] (Reporting by Ben Hirschler) ((uk.online@reuters.com;)).  Full Article

GlaxoSmithKline says for results positive in asthma study
Thursday, 2 Mar 2017 05:02am EST 

GlaxoSmithKline Plc : Feb. 23 2017 positive results for Relvar Ellipta lung function study in patients with well-controlled asthma positive headline results from a non-inferiority lung function study read more . Positive headline results from a non-inferiority lung function study . Results demonstrated statistically significant differences in favour of ics/laba combinations to FP (p<0.001). . Incidences of on-treatment serious adverse events and adverse events of special interest were consistent with known safety profile of ff/vi . Intends to submit this data to European Medicines Agency (EMA) . Gsk - study showed well-controlled asthma patients able to switch to once-daily relvar ellipta combination without compromising lung function .Gsk now intends to submit this data to european medicines agency.  Full Article

Aspen completes acquisition of a portfolio of anaesthetics with GlaxoSmithKline
Wednesday, 1 Mar 2017 02:00am EST 

Aspen Pharmacare Holdings:Aspen Holdings is pleased to announce that this transaction completed.  Full Article

GSK reports positive results in study for controlled asthma
Thursday, 23 Feb 2017 04:46am EST 

GlaxoSmithKline Plc : Positive results for Relvar Ellipta lung function study in patients with well-controlled asthma . Patients randomised to FF/VI taken once-daily maintained lung function versus those randomised to twice-daily FP/SAL, meeting study's primary endpoint . GSK now intends to submit this data to European Medicines Agency (EMA) .Incidences of on-treatment serious adverse events and adverse events of special interest were consistent with known safety profile of FF/VI,.  Full Article

More From Around the Web

BRIEF-Glaxo Smithkline Consumer Nig reports Q1 group loss before tax of 8.3 mln naira

* Q1 group loss before tax of 8.3 million naira versus profit of 167.5 million naira year ago